Merck & Co., Inc.

Merck & Co., Inc.

MRK Stock Report Card





Score: 100/100


MRK returned 23.61% in the last 12 months. Based on the other stocks in its sector with an average return of -4.24%, its performance is above average giving it a grade of 100 of 100.


Score: 68/100


21 analysts offer 12-month price forecasts for MRK. Together, they have an average target of 113.88, the most optimistic forecast put MRK at 294 within 12-months and the most pessimistic has MRK at 80.


Score: 46/100


MRK receives a 46 of 100 based on 14 indicators. 6 are bullish, 7 are bearish.


Score: 64/100


MRK has missed earnings 2 times in the last 20 quarters.


Score: 63/100


Out of the last 20 quarters, MRK has had 19 profitable quarters and has increased their profits year over year on 6 of them.


Score: 56/100


MRK has had a higher than average amount of volatility over the last 12 months giving it a grade of 56 of 100.


Score: 93/100


MRK's most recent dividend was $0.47 per share, based on a share price of $110.93. It was a payout ratio of 76.80% compared to their total earnings.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK
Drug Manufacturers—General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Power up your portfolio

Build a portfolio of the best stocks

Pluto makes it easy to build investing strategies and automate your portfolio
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.